Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
These are just some of the ways in which analysts forecast that the new wave of incredibly effective weight-loss ...
The weight-loss drug users and doctors whom The Times spoke to for this ... As powerful anti-obesity drugs become ...
In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...
Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...
Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.
The stock, which enjoys the unusual position of having all buy ratings from the 13 analysts offering coverage on FactSet, has ...
Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...